10-QPeriod: Q2 FY2014

GILEAD SCIENCES, INC. Quarterly Report for Q2 Ended Jun 30, 2014

Filed August 4, 2014For Securities:GILD

Summary

Gilead Sciences, Inc. reported a significant surge in revenue for the second quarter of 2014, primarily driven by the successful launch of its Hepatitis C drug, Sovaldi. Total revenues reached $6.53 billion, a substantial increase from $2.77 billion in the same period of the prior year, with Sovaldi alone generating $3.48 billion in sales. This performance led to a net income attributable to Gilead of $3.66 billion, or $2.20 per diluted share, a marked improvement from the previous year's quarter. The company also demonstrated strong cash generation, with cash, cash equivalents, and marketable securities increasing to $9.58 billion. Gilead continued its commitment to returning value to shareholders through significant stock repurchases, authorized a new $5 billion repurchase program, and managed its debt effectively by repaying outstanding balances. Despite increased R&D and SG&A expenses to support its growing business, Gilead's financial health appears robust, positioning it for continued growth and investment in its pipeline.

Financial Highlights

57 data points
Beta

Revenue

$6.54B

84.0% Gross Margin

Net Income

$3.66B

55.9% Net Margin

EPS (Diluted)

$2.20

Total Assets

$31.21B

Cash & Equivalents

$8.73B

Free Cash Flow

$3.93B

Financial Statements
Beta
Revenue$6.54B
Cost of Revenue$925.00M
Gross Profit$5.49B
R&D Expenses$584.00M
SG&A Expenses$614.00M
Operating Expenses$2.12B
Operating Income$4.41B
Interest Expense$102.00M
Net Income$3.66B
EPS (Basic)$2.39
EPS (Diluted)$2.20
Shares Outstanding (Basic)1.53B
Shares Outstanding (Diluted)1.66B

Key Highlights

  • 1Total revenues for Q2 2014 surged to $6.53 billion, a 141% increase year-over-year, largely due to the launch of Sovaldi.
  • 2Sovaldi generated impressive sales of $3.48 billion in its second full quarter on the market.
  • 3Net income attributable to Gilead more than quadrupled to $3.66 billion ($2.20 per diluted share) compared to Q2 2013.
  • 4The company's cash, cash equivalents, and marketable securities grew significantly to $9.58 billion.
  • 5Operating cash flow was strong at $5.75 billion for the first six months of 2014.
  • 6Gilead repurchased $1.20 billion of common stock in Q2 2014 and announced a new $5 billion share repurchase program.
  • 7Product gross margins improved substantially to 86% in Q2 2014 from 74% in Q2 2013, driven by Sovaldi's sales mix.

Frequently Asked Questions

The primary driver of Gilead's revenue growth was the strong performance of Sovaldi, its newly launched Hepatitis C medication. Sovaldi sales accounted for a significant portion of the company's total revenue increase, demonstrating its rapid market adoption.

The launch of Sovaldi significantly boosted Gilead's profitability. Net income attributable to Gilead increased dramatically in Q2 2014 compared to the prior year, driven primarily by Sovaldi's substantial sales, which also improved the company's product gross margins.

Gilead ended Q2 2014 with a strong cash position of $9.58 billion in cash, cash equivalents, and marketable securities. The company is actively managing its capital by generating substantial operating cash flows, repurchasing its own stock ($1.20 billion in Q2 2014) under an existing program, and initiating a new $5 billion repurchase program, while also repaying debt.

Yes, Gilead faces several ongoing legal proceedings, primarily related to intellectual property and patent disputes concerning sofosbuvir (Sovaldi) with companies like Roche and Idenix, as well as patent litigation with generic manufacturers. The company also mentions a Department of Justice investigation. While Gilead believes these claims are without merit, adverse outcomes could impact its business.